Sepsis Articles & Analysis

Despite decades of research, therapy for sepsis remains limited to supportive care, including early identification and intervention directed towards elimination of the physical focus of infection (commonly referred to as source control), and appropriate antibiotics. … In this issue of eBioMedicine, Baghela and colleagues present a critical and timely addition to the sepsis endotype ...

By Sepset Biosciences Inc.

Robert Hancock and Olga Peña—who lost her father to sepsis—may have found a way to diagnose the deadliest syndrome you’ve never heard of. The doctor suspected 70-year-old Augustin Peña had the flu, so he sent him home to rest and drink lots of fluids. But after three days of continuing to suffer, Peña entered the local hospital in Tolima, Colombia. His ...

By Sepset Biosciences Inc.

The NHS has saved hundreds of people from sepsis thanks to better use of digital technology in hospitals. In a major nationwide push to tackle the condition, including a one hour identification and treatment ambition, new ‘alert and action’ technology is being introduced which uses algorithms to read patients’ vital signs and alert medics to worsening conditions that are a ...

By EBME.Co.Uk Ltd.

Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful completion of its multi-center observational study using Abionic’s novel point-of-care Pancreatic Stone Protein (PSP) sepsis test on the abioSCOPE® platform. The results of the study show an anticipation of 24 hours for the diagnosis of sepsis compared to current ...

By Abionic SA

Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful closing of a CHF20 million Series C financing. The round was led by Pierangelo Bottinelli, Chairman of Symphony International Holdings Limited, and included Philippe Glatz (Chairman of two private hospitals), Peter Brabeck-Letmathe (former CEO and Chairman of Nestlé), ...

By Abionic SA

Inflammatix, a pioneering molecular diagnostics company, announced today that the National Institute of General Medical Sciences, part of the National Institutes of Health, has awarded the company a Small Business Innovation Research (NIH SBIR) Direct-to-Phase II grant of $1.7 million. The funding will be used to develop a rapid diagnostic that will identify immune subtypes ...

By Inflammatix, Inc.

Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune-mediated diseases, today announced the first enrollment in a clinical trial of the Cytovale system and IntelliSep test to aid in the rapid assessment of potential for sepsis in the emergency department (ED). The trial, A Clinical Validation Solving the Question of ...

By Cytovale Inc.

Marking “World Sepsis Day”, The Centre for Drug Research and Development (CDRD) announces the spin-off of a new company, Sepset Biosciences Inc. The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims ...

By Sepset Biosciences Inc.

CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds. Sepsis is the body’s overwhelming and life-threatening ...

By Accelerate Diagnostics, Inc.

Financing will be used to advance HostDx tests for acute infections and sepsis to commercial launch in 2021. Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced a $32 million Series C financing. The funding round included participation from existing investors Khosla Ventures, Northpond Ventures and Think.Health Ventures, and ...

By Inflammatix, Inc.

Today, Midland Memorial Hospital in Midland, Texas announced that its laboratory team took the Accelerate Pheno® system clinically live to improve care for patients with bloodstream infections and sepsis. The system will enable the laboratory’s microbiology team to deliver fast antimicrobial susceptibility results with minimum inhibitory concentrations to clinicians who serve Midland ...

By Accelerate Diagnostics, Inc.

Today, Saint Mary’s Regional Health System in Russellville, Arkansas announced that its laboratory went clinically live with the Accelerate Pheno® system, taking a leap forward in its care for patients with bloodstream infections and sepsis. The four-module system will enable the laboratory’s microbiology team to deliver fast antimicrobial susceptibility test results to clinicians ...

By Accelerate Diagnostics, Inc.

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the SeptiCyte® RAPID (developed in collaboration with Immunexpress) and one on the Idylla™ SARS-CoV-2 Test (CE-IVD) and Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD), ...

By Biocartis NV

Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal PLOS ONE evaluating its IntelliSep test in the rapid diagnosis of sepsis in the hospital emergency department. Data from the study, “Development and validation of a cellular ...

By Cytovale Inc.

Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced the publication of a health economic model that shows use of the company’s HostDxTM Sepsis test in patients suspected of acute respiratory tract infections (ARTI) in Emergency Departments is cost-effective versus standard-of-care. The study was published today in The Journal ...

By Inflammatix, Inc.

Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, has received an AACC Academy’s Distinguished Abstract Award for its abstract titled “Rapidly Assessing the Host Immune Response for the Diagnosis of Sepsis, a Prospective Multi-Site Clinical Study in the Emergency Department (ED) Employing the Leukocyte ...

By Cytovale Inc.

Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced that six studies, reporting zero or near-zero blood culture contamination rates and up to a 31% reduction in vancomycin days of therapy (DOT) using Steripath, were submitted, accepted and published in ...

By Magnolia Medical Technologies

Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced the appointment of João Fonseca, Ph.D., as Chief Technology Officer. Dr. Fonseca will oversee Inflammatix’s molecular assay development and engineering teams as the company advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification. ...

By Inflammatix, Inc.

Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF ...

By Inflammatix, Inc.

Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communications that demonstrate its ability to identify patients with bacterial versus viral infections using a data-driven approach that measures the immune system response. The molecular classifier used in the study forms the ...

By Inflammatix, Inc.